Forma Therapeutics Holdings Inc. (FMTX)
$20.01
$0.00 (0.00%)As on 21-Oct-2022 09:30EDT
Market cap
$1,008 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-190 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4
-
Face value
--
-
Shares outstanding
47,860,400
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Forma Therapeutics Holdings (FMTX)
| 40.7 | 0.4 | 125.6 | 13.4 | -- | -- | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
|---|---|
|
Forma Therapeutics Holdings (FMTX)
| -59.3 |
|
S&P Small-Cap 600
| 25.3 |
|
BSE Sensex
| 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Forma Therapeutics Holdings (FMTX)
|
20.0 | 1,007.8 | 0.0 | -190.2 | -- | -41.7 | -- | 2.3 |
| 2.2 | 93.4 | 665.5 | -43.0 | -6.0 | -32.9 | -- | 0.5 | |
| 21.0 | 2,941.2 | 4,649.0 | -13.0 | 0.0 | -0.9 | -- | 2.0 | |
| 17.6 | 814.1 | 175.5 | -702.0 | -549.2 | -- | -- | 9.5 |
Shareholding Pattern
View DetailsAbout Forma Therapeutics Holdings (FMTX)
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development... include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S. Read more
-
Pres & CEO
Mr. Frank D. Lee
-
Pres & CEO
Mr. Frank D. Lee
-
Headquarters
Watertown, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Forma Therapeutics Holdings (FMTX)
What is the current share price of Forma Therapeutics Holdings Inc (FMTX) Today?
The share price of Forma Therapeutics Holdings Inc (FMTX) is $20.01 (NASDAQ) as of 21-Oct-2022 09:30 EDT. Forma Therapeutics Holdings Inc (FMTX) has given a return of 13.44% in the last 1 years.
What is the current PB & PE ratio of Forma Therapeutics Holdings Inc (FMTX)?
Since, TTM earnings of Forma Therapeutics Holdings Inc (FMTX) is negative, P/E ratio is not available.
The P/B ratio of Forma Therapeutics Holdings Inc (FMTX) is 2.31 times as on 11-Nov-2022, a 53 discount to its peers’ median range of 4.90 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
-3.86 |
1.34 |
2020 |
-11.40 |
1.24 |
2019 |
-- |
-- |
2018 |
-- |
-- |
2021 |
-3.86 |
1.34 |
What is the 52 Week High and Low of Forma Therapeutics Holdings Inc (FMTX)?
The 52-week high and low of Forma Therapeutics Holdings Inc (FMTX) are Rs -- and Rs -- as of 08-Sep-2026.
What is the market cap of Forma Therapeutics Holdings Inc (FMTX)?
Forma Therapeutics Holdings Inc (FMTX) has a market capitalisation of $ 1,008 Mln as on 11-Nov-2022. As per SEBI classification, it is a Small Cap company.
Should I invest in Forma Therapeutics Holdings Inc (FMTX)?
Before investing in Forma Therapeutics Holdings Inc (FMTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.